Log in to save to my catalogue

Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a n...

Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a n...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2201709518

Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis

About this item

Full title

Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis

Publisher

England: BMJ Publishing Group Ltd and European League Against Rheumatism

Journal title

Annals of the rheumatic diseases, 2019-06, Vol.78 (6), p.807-816

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd and European League Against Rheumatism

More information

Scope and Contents

Contents

ObjectiveWe sought to develop the first Damage Index (DI) in systemic sclerosis (SSc).MethodsThe conceptual definition of ‘damage’ in SSc was determined through consensus by a working group of the Scleroderma Clinical Trials Consortium (SCTC). Systematic literature review and consultation with patient partners and non-rheumatologist experts produce...

Alternative Titles

Full title

Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2201709518

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2201709518

Other Identifiers

ISSN

0003-4967

E-ISSN

1468-2060

DOI

10.1136/annrheumdis-2018-214764

How to access this item